IRCCS Multimedica, Italy.
Centro Cardiologico Monzino, Italy.
Eur J Prev Cardiol. 2020 Dec;27(2_suppl):65-71. doi: 10.1177/2047487320951109.
Heart failure is a complex syndrome affecting several organs including kidney, lungs, liver, brain muscles and sympathetic system. Each of these organs might contribute to its severity and prognosis. The prognosis assessment is critical for a correct heart failure management. It has already been demonstrated that a single parameter is weaker for prognosis than different parameters combined. The Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score has been built and validated for heart failure with reduced ejection fraction (HFrEF) patients by considering cardiopulmonary exercise test data combined with clinical, laboratory and echocardiographic measurements. The betablockers treatment is a milestone in the HFrEF management. In the MECKI score database, the association of betablockers treatment with outcome has been investigated in different settings.
心力衰竭是一种影响包括肾脏、肺、肝、脑、肌肉和交感神经系统等多个器官的复杂综合征。这些器官中的每一个都可能对其严重程度和预后产生影响。预后评估对于正确的心力衰竭管理至关重要。已经证明，单一参数的预后能力弱于不同参数的组合。代谢运动试验数据与心脏和肾脏指数（MECKI）评分已被构建和验证，用于射血分数降低的心力衰竭（HFrEF）患者，通过考虑心肺运动试验数据与临床、实验室和超声心动图测量相结合。β受体阻滞剂治疗是 HFrEF 管理的一个里程碑。在 MECKI 评分数据库中，已经在不同环境下研究了β受体阻滞剂治疗与结局的关系。
